Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Common Equity: 2024-2025

Historic Common Equity for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to $242.5 million.

  • Kura Oncology's Common Equity fell 42.77% to $242.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $242.5 million, marking a year-over-year decrease of 42.77%. This contributed to the annual value of $413.6 million for FY2024, which is N/A change from last year.
  • According to the latest figures from Q3 2025, Kura Oncology's Common Equity is $242.5 million, which was down 20.60% from $305.5 million recorded in Q2 2025.
  • Over the past 5 years, Kura Oncology's Common Equity peaked at $505.1 million during Q1 2024, and registered a low of $242.5 million during Q3 2025.